New appointment at Ensysce Biosciences
This article was originally published in Scrip
Ensysce Biosciences (US) has named Dr Lynn Kirkpatrick president and CEO. Co-founder of Pro1X Pharmaceuticals, Dr Kirkpatrick was CEO from 1999 until its acquisition by Biomira in 2006. From 2006-08 she was chief scientific officer of the merged company, which changed its name to Oncothyreon in 2007.